PCSK6 and cancer: Additionally, novel molecular biomarkers are continuously being discovered (e.g., PACE4-altCT, a new isoform of proprotein convertase PACE4 [49]), and the use of advanced technologies, such as nanotechnology—with the potential to alleviate the current limitations of molecular testing—[46], or data-driven deep learning approaches—known as cross-cancer learning—[50], is gaining attention in recent years.